| Patient | Dwight D. Eisenhower |
|---|---|
| Date of birth | 1890-10-14 |
| Identifiers | MRN HR-ET015-SYN-TD; SSN (made up) 000-15-2673 |
| Document date | 1956-03-16 |
| Author | Russell Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Lipid review nine weeks after adding ezetimibe. [S]
Mr. Eisenhower returns for his lipid review. He has been back at full-time work for seven weeks, including two trips by air, without chest pain, breathlessness, or undue fatigue. He walks 40 minutes on most days and has started hitting golf balls at the practice range. He has had no muscle aches on atorvastatin and ezetimibe, and his home blood pressure averages 122/76. [S]
| Element | Detail |
|---|---|
| Interval change | Full-time work for seven weeks; air travel tolerated |
| Exercise | Walking most days; golf practice resumed |
| Medication tolerance | No myalgia on atorvastatin and ezetimibe |
| Home blood pressure | Average 122/76 |
| Nitroglycerin use | None |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fatigue or weight gain |
| Cardiovascular | Negative | No chest pain, palpitations, or edema |
| Respiratory | Negative | No breathlessness on stairs or walking |
| Musculoskeletal | Negative | No muscle aches or weakness |
| Psychiatric | Negative | Mood good; sleeping well; PHQ-2 score 0 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1955-09-24 | active | S |
| Ticagrelor 90 mg oral tablet, one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 1955-09-24 to 1956-09-28 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1955-09-24 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1955-09-25 | active | S |
| Lisinopril 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1955-09-26 to 1956-01-12 | completed | S |
| Lisinopril 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1956-01-12 | active | S |
| Ezetimibe 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1956-01-12 | active | S |
| Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet | One tablet under the tongue every 5 minutes as needed for chest pain, up to 3 doses | Sublingual route | 1955-09-24 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1956-03-16 | Body height | 178 | cm | S |
| 1956-03-16 | Body weight | 78 | kg | S |
| 1956-03-16 | Body mass index (BMI) [Ratio] | 24.6 | kg/m2 | S |
| 1956-03-16 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1956-03-16 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1956-03-16 | Heart rate | 58 | /min | S |
| 1956-03-16 | Respiratory rate | 14 | /min | S |
| 1956-03-16 | Body temperature | 36.6 | Cel | S |
| 1956-03-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1956-03-16 | Cholesterol [Mass/volume] in Serum or Plasma | 118 | mg/dL | <=199 mg/dL | Normal | S |
| 1956-03-16 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 | mg/dL | >=40 mg/dL | Normal | S |
| 1956-03-16 | Triglyceride [Mass/volume] in Serum or Plasma | 120 | mg/dL | <=149 mg/dL | Normal | S |
| 1956-03-16 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 50 | mg/dL | <=99 mg/dL | Normal | S |
| 1956-03-16 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-56 U/L | Normal | S |
| 1956-03-16 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 1956-03-16; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and energetic |
| Heart | Regular rhythm; no murmur or gallop |
| Lungs | Clear |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Anterior ST-elevation myocardial infarction about four months before intake, treated with a drug-eluting stent to the left anterior descending artery; synthetic modern episode linked to the documented 1885 anterolateral infarction | active | confirmed | I25.2 | S — Synthetic modern diagnosis; the 1955 infarction remains D in the history. |
| Coronary artery disease, single-vessel, after stenting; no angina | active | confirmed | I25.10 | S — Synthetic diagnosis supporting secondary prevention. |
| Hyperlipidemia, on high-intensity statin | active | confirmed | E78.5 | S — Synthetic diagnosis; no cholesterol value from his lifetime is used. |
| Essential hypertension | active | confirmed | I10 | S — Synthetic diagnosis; no blood pressure from his lifetime is used. |
| Former heavy cigarette smoker, quit about seven years before intake | active | confirmed | Z87.891 | S — Synthetic coded history echoing the documented heavy smoking and quitting around 1949. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing therapy, then every 3 to 12 months | Completed today | Nine weeks after adding ezetimibe, within the 4-to-12-week window of the ischemic heart disease and hyperlipidemia monographs and one week past the AMI monograph's 4-to-8-week window. LDL cholesterol 50 mg/dL, at goal |
| Laboratory | ALT | Baseline, then only with symptoms | Completed today | 26 U/L, normal; checked with the lipid panel because ezetimibe was added |
| Laboratory | Basic metabolic panel | 1 to 2 weeks after starting or changing an ACE inhibitor, then every 6 months | Up to date | Normal two weeks after the lisinopril increase; next due in about four months |
| Examination | Blood pressure, heart rate, weight and BMI, heart and lungs, edema | Every visit | Completed today | Blood pressure 124/76 mmHg, weight 78.0 kg |
| Medication safety | Antiplatelet, statin, beta-blocker, and ACE inhibitor adherence and tolerance | Every visit | Completed today | Taking all doses; no bleeding beyond bruising; no myalgia |
| Survey | Depression screen (PHQ-2) | Every visit | Completed today | Score 0 |
| Self-management | Tobacco use | Every visit | Completed today | Abstinent |
| Self-management | Physical activity and diet | Every visit | Completed today | At least 150 minutes a week of moderate activity |
| Imaging | Stress testing or repeat echocardiography | Only with new or changing symptoms | Not indicated | No symptoms; routine surveillance testing is not recommended |
Goal progress:
Guideline basis: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026)
Follow-up: Coronary disease review in about two months. Next scheduled visit 1956-05-11: seven-month coronary disease review after return to full-time work. [S]